Blair William & Co. IL Takes $33,000 Position in Rein Therapeutics Inc. $RNTX

Blair William & Co. IL bought a new stake in shares of Rein Therapeutics Inc. (NASDAQ:RNTX) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 23,622 shares of the company’s stock, valued at approximately $33,000.

Rein Therapeutics Stock Performance

Shares of RNTX opened at $1.22 on Monday. The business has a 50-day moving average of $1.22 and a 200 day moving average of $1.51. Rein Therapeutics Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $4.40. The firm has a market cap of $28.43 million, a P/E ratio of -0.45 and a beta of 1.14.

Rein Therapeutics (NASDAQ:RNTX) last issued its earnings results on Thursday, August 14th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.06). As a group, research analysts predict that Rein Therapeutics Inc. will post -1.56 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on RNTX shares. Brookline Capital Management lowered Rein Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Weiss Ratings reissued a “sell (e+)” rating on shares of Rein Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright began coverage on Rein Therapeutics in a report on Monday, September 22nd. They issued a “buy” rating and a $10.00 price objective for the company. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $10.00.

About Rein Therapeutics

Rein Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers.